Leukocytosis Management in Psoriasis Patient on Prednisone with Diabetes
The elevated WBC count is most likely due to prednisone-induced leukocytosis, which is an expected pharmacologic effect that can persist throughout therapy and does not require treatment unless infection is suspected. 1, 2
Understanding Prednisone-Induced Leukocytosis
Prednisone causes predictable leukocytosis through several mechanisms:
- WBC counts can exceed 20,000/mm³ as early as the first day of treatment and persist for the duration of therapy 2
- The elevation is dose-dependent but occurs even with small doses administered over prolonged periods 2
- The leukocytosis is predominantly neutrophilic (polymorphonuclear cells), accompanied by monocytosis, eosinopenia, and variable lymphopenia 2
- Maximal WBC elevation typically occurs within two weeks, then decreases slightly but remains above baseline throughout treatment 2
Critical Distinction: Drug Effect vs. Infection
The key to management is differentiating benign drug-induced leukocytosis from infection-related leukocytosis, which is particularly important given that prednisone increases infection risk and masks infection signs 1:
Features suggesting infection (requires workup):
- Left shift >6% band forms
- Toxic granulation in neutrophils
- Fever or localizing symptoms
- Clinical deterioration
Features of pure prednisone effect (no action needed):
- Elevated WBC without left shift
- Absence of toxic granulation
- Stable clinical status
- No fever or localizing signs
Specific Evaluation Algorithm
Review the peripheral smear immediately:
- Look for band forms percentage
- Assess for toxic granulation
- If <6% bands and no toxic changes → likely drug effect, no further workup needed 2
If left shift or toxic granulation present:
Monitor for infection risk factors specific to this patient:
- Diabetes increases infection susceptibility
- Prednisone suppresses immune response and masks infection signs 1
- The combination creates particularly high infection risk
Diabetes-Specific Considerations
This patient's diabetes complicates the clinical picture because:
- Diabetes itself increases infection risk
- Prednisone worsens glycemic control, further increasing infection susceptibility
- Poor glucose control in diabetic psoriasis patients is associated with worse outcomes 3
- Ensure hemoglobin A1C and fasting glucose are monitored given the psoriasis-diabetes association 3
Management Recommendations
If infection is ruled out (no left shift, no toxic granulation, clinically stable):
- No intervention needed for the leukocytosis itself
- Continue prednisone as prescribed for psoriasis
- Monitor for infection development throughout therapy
- Optimize diabetes control to minimize infection risk
If infection cannot be excluded:
- Pursue full infectious workup before attributing leukocytosis solely to prednisone
- Consider prednisone dose reduction if infection confirmed 1
- Treat infection aggressively given immunocompromised state
Common Pitfalls to Avoid
- Do not assume all leukocytosis in steroid-treated patients is benign - always assess for left shift and toxic changes 2
- Do not overlook opportunistic infections - prednisone increases risk of tuberculosis, fungal infections, strongyloides, and viral reactivation 1
- Do not ignore the diabetes - poor glycemic control compounds infection risk and should be optimized 3
- Do not continue high-dose prednisone long-term for psoriasis - consider transitioning to safer systemic therapies like biologics, which have better safety profiles in diabetic patients 4, 3
Long-Term Considerations
Given this patient has both psoriasis and diabetes, strongly consider transitioning from prednisone to alternative systemic therapy such as biologics (TNF inhibitors, IL-17 or IL-23 inhibitors) or methotrexate, which are guideline-recommended for moderate-to-severe psoriasis and have more favorable long-term safety profiles 4, 3. Prednisone is not a preferred long-term treatment for psoriasis due to systemic side effects and metabolic complications.